for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nippon Shinyaku Co., Ltd.

4516.T

Latest Trade

9,230.00JPY

Change

-130.00(-1.39%)

Volume

167,600

Today's Range

9,220.00

 - 

9,370.00

52 Week Range

6,170.00

 - 

9,710.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
9,360.00
Open
9,360.00
Volume
167,600
3M AVG Volume
4.80
Today's High
9,370.00
Today's Low
9,220.00
52 Week High
9,710.00
52 Week Low
6,170.00
Shares Out (MIL)
67.35
Market Cap (MIL)
657,553.90
Forward P/E
31.69
Dividend (Yield %)
0.75

Next Event

Q2 2020 Nippon Shinyaku Co Ltd Earnings Release

Latest Developments

More

Zogenix Enters Exclusive Distribution Agreement With Nippon Shinyaku For Fintepla® In Japan

Nippon Shinyaku Co's sales likely rose 20 pct to nearly 100 bln yen in fiscal 2016 - Nikkei

Actelion wins Swiss approval of uptravi for form of high blood pressure

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.

Industry

Biotechnology & Drugs

Contact Info

14, Nishinosho Monguchi-cho,

Kisshoin, Minami-ku

+81.75.3211111

http://www.nippon-shinyaku.co.jp

Executive Leadership

Shigenobu Maekawa

President, Representative Director

Tsugio Tanaka

Managing Director

Yoshiro Yura

Executive Director

Tetsuyasu Yuno

Chief Director of Sales, Director

Hitoshi Saito

Executive Officer, Senior Director of Research & Development Planning in Main Research & Development Unit, Director

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (JPY)

2017

174.420

2018

192.310

2019

242.040

2020(E)

295.388
Price To Earnings (TTM)
36.46
Price To Sales (TTM)
5.65
Price To Book (MRQ)
4.63
Price To Cash Flow (TTM)
31.79
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
12.44
Return on Equity (TTM)
10.63

Latest News

Latest News

BRIEF-Nippon Shinyaku Co's sales likely rose 20 pct to nearly 100 bln yen in fiscal 2016 - Nikkei

* Nippon Shinyaku Co Ltd appears to have generated around 15.5 billion yen in group operating profit in fiscal 2016 - Nikkei

BRIEF-Jazz pharmaceuticals and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

* Jazz Pharmaceuticals Plc - co and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up